CA
NZ
UK
AU
IND
US
A Form 4 filed with the SEC on August 14, 2026, discloses that Pablo J. Cagnoni, President and Global Head of R&D at Incyte Corp (NASDAQ:INCY), disposed of 10,803 shares of common stock on August 12, 2026, pursuant to a Rule 10b5-1 trading plan.
Emily M. Leproust, Chief Executive Officer and Director of Twist Bioscience Corp (NASDAQ:TWST), filed a Form 4 on August 14, 2026, reporting a stock option exercise and subsequent sale of common shares on August 12, 2026, conducted under a pre-established Rule 10b5-1 trading plan.
Tilman J. Fertitta, a director and 10% owner of Wynn Resorts Ltd (NASDAQ:WYNN), filed a Form 4 on August 14, 2026, disclosing the sale of three blocks of call option contracts on Wynn Resorts common stock, all transacted on August 12, 2026.
A Form 4 filed on August 14, 2026 discloses that Katryn Blake, a director of Twist Bioscience Corp (NASDAQ:TWST), sold 2,240 shares of common stock on August 12, 2026 to cover tax liability associated with the vesting of Restricted Stock Units.
Kevin Waters, Executive Vice President and CFO of PROCEPT BioRobotics Corp (NASDAQ:PRCT), filed a Form 4 on August 14, 2026, disclosing the acquisition of restricted stock units and a stock option grant dated August 13, 2026.
William Carroll Murphy, Chief Legal & Strategy Officer of Oklo Inc., filed a Statement of Changes in Beneficial Ownership on August 14, 2026, reporting the vesting of restricted stock units on August 12, 2026.
Barry L. Templin, Executive Vice President and Chief Technology Officer of PROCEPT BioRobotics Corp (NASDAQ:PRCT), filed a Form 4 on August 14, 2026, disclosing the acquisition of 26,246 restricted stock units and a stock option covering 36,312 shares of common stock, both granted on …
A Form 4 filed on August 14, 2026 discloses that Alaleh Nouri, Executive Vice President, Chief Legal Officer, and Corporate Secretary of PROCEPT BioRobotics Corp (NASDAQ:PRCT), acquired 22,965 restricted stock units and a stock option covering 31,773 shares of common stock on August 13, …
Lawrence James Lawson III, a Director and 10% Owner of Lincoln International, Inc., filed a Form 4 on August 14, 2026, disclosing the acquisition of 153,711 shares of Class A Common Stock on August 12, 2026.
Adam M. Veness, Senior Vice President, General Counsel and Secretary of Dianthus Therapeutics, Inc. (NASDAQ:DNTH), filed a statement of changes in beneficial ownership on August 14, 2026, reporting a stock option exercise dated August 13, 2026.
Please wait processing your request...